Brokerages Expect Assembly Biosciences Inc (NASDAQ:ASMB) Will Post Earnings of -$0.78 Per Share

Brokerages expect Assembly Biosciences Inc (NASDAQ:ASMB) to post earnings of ($0.78) per share for the current quarter, Zacks reports. Four analysts have provided estimates for Assembly Biosciences’ earnings. The highest EPS estimate is ($0.70) and the lowest is ($0.85). Assembly Biosciences reported earnings per share of ($0.96) in the same quarter last year, which indicates a positive year over year growth rate of 18.8%. The firm is scheduled to issue its next quarterly earnings results on Thursday, November 5th.

On average, analysts expect that Assembly Biosciences will report full year earnings of ($2.20) per share for the current financial year, with EPS estimates ranging from ($2.33) to ($2.07). For the next fiscal year, analysts forecast that the business will post earnings of ($3.40) per share, with EPS estimates ranging from ($3.85) to ($2.73). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Assembly Biosciences.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $0.19 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.03) by $0.22. Assembly Biosciences had a negative net margin of 136.24% and a negative return on equity of 30.14%. The firm had revenue of $39.38 million for the quarter, compared to the consensus estimate of $30.54 million.

Several research firms have weighed in on ASMB. William Blair restated a “buy” rating on shares of Assembly Biosciences in a report on Thursday, June 25th. Zacks Investment Research downgraded shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, June 23rd. ValuEngine downgraded shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a report on Thursday, July 2nd. SVB Leerink reiterated an “outperform” rating on shares of Assembly Biosciences in a report on Friday, August 28th. Finally, BidaskClub downgraded shares of Assembly Biosciences from a “sell” rating to a “strong sell” rating in a report on Friday, October 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $41.75.

ASMB traded up $0.20 during trading on Friday, hitting $15.62. 153,313 shares of the company’s stock were exchanged, compared to its average volume of 246,293. The business’s 50 day moving average is $17.49 and its two-hundred day moving average is $19.81. Assembly Biosciences has a fifty-two week low of $10.23 and a fifty-two week high of $27.84. The stock has a market cap of $513.20 million, a P/E ratio of -6.20 and a beta of 1.21.

Several hedge funds have recently made changes to their positions in the company. Two Sigma Advisers LP raised its holdings in shares of Assembly Biosciences by 20.1% in the second quarter. Two Sigma Advisers LP now owns 85,500 shares of the biopharmaceutical company’s stock valued at $1,994,000 after purchasing an additional 14,300 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Assembly Biosciences by 15.0% during the second quarter. Charles Schwab Investment Management Inc. now owns 211,076 shares of the biopharmaceutical company’s stock valued at $4,923,000 after buying an additional 27,605 shares during the period. AQR Capital Management LLC grew its position in Assembly Biosciences by 68.5% during the second quarter. AQR Capital Management LLC now owns 19,870 shares of the biopharmaceutical company’s stock valued at $463,000 after buying an additional 8,076 shares during the period. Engineers Gate Manager LP bought a new position in Assembly Biosciences during the second quarter valued at about $235,000. Finally, California State Teachers Retirement System grew its position in Assembly Biosciences by 7.1% during the second quarter. California State Teachers Retirement System now owns 46,271 shares of the biopharmaceutical company’s stock valued at $1,079,000 after buying an additional 3,083 shares during the period. Institutional investors own 91.23% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Recommended Story: Pattern Day Trader

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.